NYSE:QGENQiagen Stock Price, Forecast & News

Qiagen's stock was trading at $41.10 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, QGEN shares have increased by 19.1% and is now trading at $48.93.
View which stocks have been most impacted by Coronavirus.

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Qiagen in the last year. There are currently 1 sell rating, 14 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Qiagen.

Qiagen is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020.
View our earnings forecast for Qiagen.

Qiagen NV (NYSE:QGEN) posted its quarterly earnings results on Wednesday, May, 6th. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.07. The firm earned $372.10 million during the quarter, compared to the consensus estimate of $342.71 million. Qiagen had a negative net margin of 2.01% and a positive return on equity of 13.80%. The business's revenue was up 6.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.27 EPS.
View Qiagen's earnings history.

Qiagen updated its second quarter 2020 IntraDay earnings guidance on Monday, July, 13th. The company provided EPS guidance of 0.56-0.56 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.42. The company issued revenue guidance of $443-443 million, compared to the consensus revenue estimate of $417.3 million.

18 analysts have issued 1-year price targets for Qiagen's stock. Their forecasts range from $28.00 to $48.00. On average, they expect Qiagen's share price to reach $36.73 in the next twelve months. This suggests that the stock has a possible downside of 24.9%.
View analysts' price targets for Qiagen.

Media headlines about QGEN stock have trended somewhat negative on Tuesday, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Qiagen earned a media sentiment score of -1.7 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future.
View the latest news about Qiagen.

Qiagen saw a increase in short interest in the month of July. As of July 15th, there was short interest totaling 3,830,000 shares, an increase of 15.0% from the June 30th total of 3,330,000 shares. Based on an average daily volume of 1,130,000 shares, the days-to-cover ratio is presently 3.4 days. Currently, 1.7% of the shares of the company are short sold.
View Qiagen's Current Options Chain.

Some companies that are related to Qiagen include Biogen (BIIB), Seattle Genetics (SGEN), Moderna (MRNA), BioNTech (BNTX), NOVOZYMES A/S/S (NVZMY), Neurocrine Biosciences (NBIX), argenx (ARGX), BIO-TECHNE (TECH), Novavax (NVAX), Repligen (RGEN), Crispr Therapeutics (CRSP), Acceleron Pharma (XLRN), Adaptive Biotechnologies (ADPT), Allogene Therapeutics (ALLO) and Spark Therapeutics (ONCE).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Qiagen investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Netflix (NFLX), Pfizer (PFE), Twitter (TWTR), Micron Technology (MU), Paypal (PYPL), QUALCOMM (QCOM), Boeing (BA) and Alibaba Group (BABA).

Qiagen trades on the New York Stock Exchange (NYSE) under the ticker symbol "QGEN."

Qiagen's stock is owned by many different institutional and retail investors. Top institutional investors include ARP Americas LP (0.94%), First Trust Advisors LP (0.71%), Frontier Capital Management Co. LLC (0.05%), Raymond James & Associates (0.04%), Strs Ohio (0.02%) and Stone Ridge Asset Management LLC (0.02%).

QGEN stock was sold by a variety of institutional investors in the last quarter, including Brinker Capital Inc., Frontier Capital Management Co. LLC, Nisa Investment Advisors LLC, Envestnet Asset Management Inc., Raymond James & Associates, Stone Ridge Asset Management LLC, and Coastal Investment Advisors Inc..

QGEN stock was purchased by a variety of institutional investors in the last quarter, including ARP Americas LP, Strs Ohio, Vident Investment Advisory LLC, Vident Investment Advisory LLC, First Trust Advisors LP, Exane Derivatives, Actinver Wealth Management Inc., and Assenagon Asset Management S.A..

Shares of QGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of QGEN stock can currently be purchased for approximately $48.93.

Qiagen has a market capitalization of $11.14 billion and generates $1.53 billion in revenue each year. The company earns $-41,460,000.00 in net income (profit) each year or $1.43 on an earnings per share basis. Qiagen employs 5,096 workers across the globe.

The official website for Qiagen is www.qiagen.com.

Qiagen's mailing address is HULSTERWEG 82, VENLO P7, 5912. The company can be reached via phone at 31-77-355-6600 or via email at [email protected]